HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Prestige Brands

This article was originally published in The Rose Sheet

Executive Summary

Revenue for firm's personal-care segment, which includes Denorex dandruff shampoos, Prell hair care and Cutex nail-care products, totaled $4.5 million in the fourth quarter, or $1.3 million less than the comparable prior-year quarter, Prestige reports during year-end earnings call. For summer, company will introduce a manicure pen to its Cutex line as it continues to "seek value-added ways to differentiate ourselves from private-label competition in the nail polish remover category." Additionally, brand will return to "iconic" clear bottle for its Cutex liquid business. Prestige Brands' net Q4 sales rose 3% to $80.4 million and net income grew 24% to $10.4 million, firm notes. For fiscal 2008, Prestige Brands' net revenue grew 3 % to $326.6 million, though net income fell 6 % to $33.9 million due to a favorable tax benefit in 2007...

You may also be interested in...

Medicare Retail Drug Spending Accelerates In 2018 Despite Price Declines

Prices for retail drugs across US payers decreased for the first time in years, driven by a drop in generic prices and “little to no growth” in prices for brands.

Pfizer's Bourla: "I Think We Forgot What It Looks Like To Grow"

The big pharma CEO reflected on his first year of leadership at Pfizer during the Forbes Healthcare Summit and talked about executing on a plan to deliver 6% growth through 2026. 

On CRN Challenge, Nexus Formulas Gets Lesson On Supporting Ad Claims For Supplements

So full of errors were the firm's online ads for its Plavinol supplement, the National Advertising Division noted support for some claims contained "many of the same flaws" as others. The prevalence of problems prompted NAD to go its "scope of review" and note unclear instructions on Plavinol labels.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts